Deloitte May 24, 2024

Explore three innovative patient financial solutions

The expanding landscape for cell and gene therapies (CGT) promises to transform treatment for oncology, rare diseases, and other diseases. However, due to the high cost of cell and gene therapies, financial innovation may be necessary to help drive the availability and accessibility of these therapies. Here, we suggest three cell and gene therapy pricing models that could change the way CGT are financed.

Transformative therapies require innovative payment models

The cell and gene therapy landscape continues to change at an unprecedented pace—14 CGTs are in the US market today, and an estimated 30–40 manufacturers have CGTs in their near-term pipelines. Some estimates suggest that approximately 100,000...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Patient / Consumer, Pharma / Biotech, Provider
Seattle biotech startup Bonum upgrades offices, expands team in its pursuit of cancer drugs
Pfizer, Valneva inch closer to FDA approval of 1st Lyme disease vaccine
New Gene Therapy for Muscular Dystrophy May Facilitate Development of Others
Weight Loss Drugs’ Effects Could Be Improved by Priming Melanocortin System
J&J IRA pricing offer is in, as it sticks with 2025 guidance

Share This Article